- Puma Biotechnology recently reported their Q2 earnings that revealed a beat on EPS and revenue. Unfortunately, the market continues to crush PBYI, which is down ~50% from February.
- The company reported respectable sequential growth and improvements in commercial trends. It appears the company's commercial plan is showing some traction.
- The company’s Q2 earnings report and conference call has provided me with enough confidence to bring my PBYI position out of mothball and start trading the ticker on technical dips.
For further details see:
Puma Bio: Recent Sell-Off Brings My Position Out Of Mothball